About KromaTiD
KromaTiD is a company based in Fort Collins (United States) founded in 2007.. KromaTiD has raised $14.54 million across 13 funding rounds from investors including HHS, Broadoak Capital Partners and NHGRI. KromaTiD offers products and services including KROMASURE™ Platform, KROMASURE™ Screen, KROMASURE™ KBand, KROMASURE™ InSite, and KROMASURE™ PinPoint. KromaTiD operates in a competitive market with competitors including Inflammatix, Agendia, PathogenDX, Affymetrix and InDevR, among others.
- Headquarter Fort Collins, United States
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$14.54 M (USD)
in 13 rounds
-
Latest Funding Round
$7.13 M (USD), Series A
Jul 01, 2025
-
Investors
HHS
& 3 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of KromaTiD
KromaTiD offers a comprehensive portfolio of products and services, including KROMASURE™ Platform, KROMASURE™ Screen, KROMASURE™ KBand, KROMASURE™ InSite, and KROMASURE™ PinPoint. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Offers single-cell insights for chromosomal integrity in therapy research
Detects chromosome mutations and structural variants
Provides G-Banding for variant analysis
Visualizes structural variants and transgene inserts
Delivers custom probes for detailed genomic testing
Unlock access to complete
Unlock access to complete
Unlock access to complete
Funding Insights of KromaTiD
KromaTiD has successfully raised a total of $14.54M across 13 strategic funding rounds. The most recent funding activity was a Series A round of $7.13 million completed in July 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 13
- Last Round Series A — $7.1M
-
First Round
First Round
(05 Sep 2013)
- Investors Count 4
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2025 | Amount | Series A - KromaTiD | Valuation |
investors |
|
| Jan, 2024 | Amount | Series A - KromaTiD | Valuation |
investors |
|
| Apr, 2021 | Amount | Series A - KromaTiD | Valuation | Broadoak Capital Partners |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in KromaTiD
KromaTiD has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, Broadoak Capital Partners and NHGRI. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location | |
|
Investment banking services are offered in the United States.
|
Founded Year | Domain | Location | |
|
Public health and human services are overseen by HHS.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by KromaTiD
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - KromaTiD
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Kromatid Comparisons
Competitors of KromaTiD
KromaTiD operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Inflammatix, Agendia, PathogenDX, Affymetrix and InDevR, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Provider of diagnostic solutions for systemic infections
|
|
| domain | founded_year | HQ Location |
Genomic diagnostic products for cancer treatment are provided.
|
|
| domain | founded_year | HQ Location |
Provider of DNA-based pathogen testing kits
|
|
| domain | founded_year | HQ Location |
Provider of technologies for multiplex and simultaneous analysis of biological systems at the cell, protein, and gene level
|
|
| domain | founded_year | HQ Location |
Biotherapeutics, vaccines, and diagnostic products are manufactured and developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Kromatid
Frequently Asked Questions about KromaTiD
When was KromaTiD founded?
KromaTiD was founded in 2007 and raised its 1st funding round 6 years after it was founded.
Where is KromaTiD located?
KromaTiD is headquartered in Fort Collins, United States. It is registered at Fort Collins, Colorado, United States.
Is KromaTiD a funded company?
KromaTiD is a funded company, having raised a total of $14.54M across 13 funding rounds to date. The company's 1st funding round was a Series A of $2M, raised on Sep 05, 2013.
What does KromaTiD do?
Provider of molecular and genetic tests for detection of disease-causing mutations, including inversions and translocations, in a single test. Based on its patented Directional Genomic Hybridization (dGH), KromaTiDs assays generate the sequence, location, and orientation data from single cells, making them ideal for mixed cell population studies. KromaTiDs research products and services help in a deeper understanding of genetic diseases, including cancers and developmental disorders.
Who are the top competitors of KromaTiD?
KromaTiD's top competitors include Inflammatix, PathogenDX and Agendia.
What products or services does KromaTiD offer?
KromaTiD offers KROMASURE™ Platform, KROMASURE™ Screen, KROMASURE™ KBand, KROMASURE™ InSite, and KROMASURE™ PinPoint.
Who are KromaTiD's investors?
KromaTiD has 4 investors. Key investors include HHS, Broadoak Capital Partners, NHGRI, and First Capital Ventures.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.